Navigating the EU regulatory landscape is critical for successful product launches.
Choosing the right authorization pathway is not just procedural, it drives timelines, market reach, and compliance.
Understanding the Pathways:
Centralized Procedure (CP): Mandatory for innovative, biotech, and orphan medicines. Single EMA approval grants access to all EU/EEA countries.
Decentralized Procedure (DCP): Enables simultaneous submissions in multiple EU countries for products not yet authorized anywhere.
Mutual Recognition Procedure (MRP): Leverages an existing national authorization; other member states recognize the approval.
National Procedure (NP): Country-specific approval for products intended for one EU member state.
Key Considerations When Choosing a Pathway:
- Product Type: Innovative, generic, biosimilar, or orphan drug
- Target Market: Single country vs. multiple member states
- Reference Products: Existing approvals that can be leveraged
- Regulatory Complexity & Timelines: Optimize for faster patient access
- Lifecycle Strategy: Future variations, renewals, or line extensions
Why It Matters:
A clear EU authorization strategy minimizes review delays, ensures compliance, and accelerates patient access. Proactive planning with EMA and national authorities, backed by scientific rationale, is the cornerstone of success.
Pharma professionals who master this decision-making process can reduce uncertainties, strengthen regulatory confidence, and strategically position products across Europe.
Read also: Regulatory CMC Comparison | US vs. EU Market
Resource Person: Kaunain Kareem Khan